Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Masaki Komatsubara"'
Autor:
Hiroyuki Nagase, Jun Tamaoki, Takeo Suzuki, Yasuko Nezu, Masayuki Katsumata, Masaki Komatsubara, George Mu, Shibing Yang, Ashley L. Cole, Rafael Alfonso‐Cristancho
Publikováno v:
Clinical and Translational Allergy, Vol 11, Iss 8, Pp n/a-n/a (2021)
Externí odkaz:
https://doaj.org/article/508a5b3e657340bebc1c7dcaf53c1467
Autor:
Terufumi Shimoda, Hiroshi Odajima, Arisa Okamasa, Minako Kawase, Masaki Komatsubara, Bhabita Mayer, Steven Yancey, Hector Ortega
Publikováno v:
Allergology International, Vol 66, Iss 3, Pp 445-451 (2017)
Background: The MENSA trial assessed the efficacy and safety of mepolizumab in patients with severe eosinophilic asthma. This report describes the efficacy and safety of mepolizumab in Japanese patients from MENSA. Methods: A post hoc analysis of the
Externí odkaz:
https://doaj.org/article/af810f598c7e47d2ae3d79659ee6958d
Publikováno v:
Allergology International, Vol 64, Iss 1, Pp 60-65 (2015)
Background: Fluticasone furoate nasal spray (FFNS) is a glucocorticoid developed for the treatment of allergic rhinitis (AR). This study aimed to assess the safety, efficacy, and systemic exposure of FFNS in Japanese children with perennial AR (PAR).
Externí odkaz:
https://doaj.org/article/33c322d05004416196be66356fa5ef9e
Publikováno v:
Allergology International, Vol 63, Iss 4, Pp 543-551 (2014)
Background:: Fluticasone furoate nasal spray (FFNS) is a glucocorticoid developed for the treatment of allergic rhinitis (AR). This is the first randomized clinical trial to assess the efficacy and safety of FFNS in Japanese children with perennial A
Externí odkaz:
https://doaj.org/article/09c18439311849c1a589539263cc8b62
Autor:
Rafael Alfonso-Cristancho, George Mu, Takeo Suzuki, Ashley L. Cole, Masayuki Katsumata, Yasuko Nezu, Jun Tamaoki, Masaki Komatsubara, Hiroyuki Nagase, Shibing Yang
Publikováno v:
Clinical and Translational Allergy
Clinical and Translational Allergy, Vol 11, Iss 8, Pp n/a-n/a (2021)
Clinical and Translational Allergy, Vol 11, Iss 8, Pp n/a-n/a (2021)
Background: Mepolizumab reduces exacerbations and oral corticosteroid (OCS) use in randomized controlled trials of patients with severe eosinophilic asthma. This study evaluated the effectiveness of mepolizumab in patients with severe asthma in real-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36c9df8558f1005ebb7f6c2b2b73257f
https://pubmed.ncbi.nlm.nih.gov/34708944
https://pubmed.ncbi.nlm.nih.gov/34708944
Autor:
Hiroyuki Nagase, Jun Tamaoki, Takeo Suzuki, Yasuko Nezu, Shoko Akiyama, Ashley L. Cole, Shibing Yang, George Mu, Masayuki Katsumata, Masaki Komatsubara, Rafael Alfonso-Cristancho
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 75:102130
To investigate the changes in asthma exacerbation, as well as in oral corticosteroid (OCS) use, exacerbation-related healthcare resource utilization (HRU), and healthcare costs before and after mepolizumab treatment initiation in patients with severe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0395c6b50735b521829b7bc9dbbe3b71
https://doi.org/10.1016/j.pupt.2022.102130
https://doi.org/10.1016/j.pupt.2022.102130
Autor:
Takeo Suzuki, Ashley L. Cole, Shibing Yang, Masaki Komatsubara, Yasuko Nezu, Jun Tamaoki, George Mu, R. Alfonso Cristancho, Hiroyuki Nagase, S. Akiyama, Masayuki Katsumata
Publikováno v:
TP10. TP010 CLINICAL AND POPULATION-LEVEL STUDIES OF ASTHMA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::326beee5d6b4c26777d4d1ae9372c085
https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1429
https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1429
Autor:
George Mu, Takeo Suzuki, Ashley L. Cole, Masayuki Katsumata, Hiroyuki Nagase, Jun Tamaoki, Shibing Yang, Rafael Alfonso, Yasuko Nezu, Masaki Komatsubara
Publikováno v:
Airway pharmacology and treatment.
Background: Mepolizumab (MEPO) 100mg SC is indicated for severe eosinophilic asthma, which is characterized by persistent eosinophilic inflammation and recurrent exacerbations despite high-level therapy. This study evaluated MEPO effectiveness in red
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1116059a9335dc4a9b45b9d24542147
https://doi.org/10.1183/13993003.congress-2020.2219
https://doi.org/10.1183/13993003.congress-2020.2219
Autor:
Minako Kawase, Steven W. Yancey, Hector Ortega, Hiroshi Odajima, Arisa Okamasa, Masaki Komatsubara, Terufumi Shimoda, Bhabita Mayer
Publikováno v:
BASE-Bielefeld Academic Search Engine
Allergology International, Vol 66, Iss 3, Pp 445-451 (2017)
Allergology International, Vol 66, Iss 3, Pp 445-451 (2017)
Background The MENSA trial assessed the efficacy and safety of mepolizumab in patients with severe eosinophilic asthma. This report describes the efficacy and safety of mepolizumab in Japanese patients from MENSA. Methods A post hoc analysis of the J
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6af13d4b474b0c36b2cb21888387c32f
https://doi.org/10.1016/j.alit.2016.11.006
https://doi.org/10.1016/j.alit.2016.11.006
Publikováno v:
Allergy and Asthma Proceedings. 30:84-94
Fluticasone furoate nasal spray (FFNS) is a novel, enhanced-affinity glucocorticoid administered in a unique side-actuated device for the treatment of allergic rhinitis. No previous clinical studies have compared the efficacy of FFNS with another int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6669914d95c1de87554181f0b436e876
https://doi.org/10.2500/aap.2009.30.3182
https://doi.org/10.2500/aap.2009.30.3182